GILD up +1.75% percent right now. $GILD High is at 109.32 and the Low 107.93 with current volume of 11,587,055.
Recent News posted below.
GILD Gilead Sciences Recent Headline News
Merck Down On Hepatitis C Data; Gilead Rises
at Investor's Business Daily - 1 hr 54 mins ago
Big pharma Merck (MRK) was down nearly 2% on the stock market today after the latest data from its hepatitis C pipeline underwhelmed the Street. On Sunday at the annual conference of the American Association for the Study of Liver Disease, Merck...
JNJ: 108.58 (+0.38), GILD: 107.47 (+1.02), ACHN: 12.54 (+2.43), MRK: 59.06 (-0.28), ABBV: 63.59 (+2.09), BMY: 58.54 (+0.22)
Watch for Shares of Gilead Sciences (GILD) to Approach Resistance at $109.86
Comtex SmarTrend(R) - 2 hrs 13 mins ago
Shares of Gilead Sciences (NASDAQ:GILD) opened today above their pivot of $107.24 and have already reached the first level of resistance at $108.16. Analysts will be watching for a cross of the next upside pivot targets of $109.86 and $112.48.
GILD: 107.47 (+1.02)
Buyside Buzz on Gilead, Regulus From This Year's Liver Meeting
at The Street - 2 hrs 28 mins ago
Here's a quick sketch of the Wall Street gossip mill emerging from the 'Liver Meeting.'
GILD: 107.47 (+1.02), ACHN: 12.55 (+2.44), RGLS: 23.00 (+0.92), ABBV: 63.59 (+2.09)
Early Glance: Biotechnology companies
AP - 2 hrs 40 mins ago
NEW YORK (AP) — Shares of some top biotechnology companies are up at 10 a.m.:
GILD: 107.47 (+1.02), AMGN: 162.00 (+1.75), CELG: 107.63 (+1.18)
Premarket: Stock Futures Mixed; Gilead Climbs On Merck News
at Investor's Business Daily - Mon Nov 10, 7:59AM CST
Stock futures shifted from thin, early losses to mixed trade ahead of Monday's open. Nasdaq 100 futures shed losses and were up a narrow 3.5 points. Dow futures remained 2.9 points below fair market value. S&P 500 futures were flat. The stock market...
WWAV: 35.75 (-1.18), GOGO: 15.46 (-1.18), GILD: 107.47 (+1.02), MRK: 59.06 (-0.28), CMCM: 20.90 (+0.70), DF: 16.36 (+1.94)
Earnings Forecast Buzz for Alibaba, Genworth Financial, Gilead Sciences, Zynga, Abercrombie & Fitch, and Plug Power
PR Newswire - Mon Nov 10, 7:45AM CST
EarningForecast.com has issued earnings forecast research with special focus on financial performance of the following stocks: Alibaba (NYSE:BABA), Genworth Financial (NYSE:GNW), Gilead Sciences (NASDAQ:GILD), Zynga (NASDAQ:ZNGA), Abercrombie & Fitch (NYSE:ANF), and Plug Power (NASDAQ
LUG).
GILD: 107.47 (+1.02), PLUG: 5.24 (-0.06), ANF: 28.53 (-0.97), ZNGA: 2.45 (+0.02), GNW: 8.31 (-0.10), BABA: 117.12 (+2.56)
3 Drugs That Make Gilead Sciences' Harvoni Look Cheap
Todd Campbell, The Motley Fool - Motley Fool - Mon Nov 10, 6:31AM CST
Source: Bill Brooks/Flickr Healthcare costs are the leading cause of bankruptcy, so it's little wonder that people are up in arms over the cost of newly launched medicine like Gilead Sciences Harvoni. Gilead set the price of a 12-week...
GILD: 107.47 (+1.02), BMY: 58.54 (+0.22), NVS: 92.34 (+0.58)
Merck's Shortened Hep C Regimens Fall Short of Cure-Rate Goal
at The Street - Sun Nov 09, 5:23PM CST
A triple therapy combining two experimental Merck drugs with Gilead's Sovaldi yielded interim hepatitis C cure rates for ranging from 80% to 87% following six to eight weeks of treatment.
GILD: 107.47 (+1.02), MRK: 59.06 (-0.28), ABBV: 63.59 (+2.09)
5 Prescription Drugs Selling Like Hot Cakes
Todd Campbell, The Motley Fool - Motley Fool - Sun Nov 09, 9:01AM CST
Considering that 90% of prescription drugs being developed by biotechnology companies will fail during clinical trials, it can be tough to know which biotech stocks to seize upon and which stocks to shun. Instead of focusing on unproven...
MDVN: 109.33 (-3.44), JNJ: 108.58 (+0.38), BIIB: 325.03 (+4.28), PTLA: 27.33 (-0.06), GILD: 107.47 (+1.02), CELG: 107.64 (+1.19)
3 Biotech Stocks to Watch in November
Motley Fool Staff - Motley Fool - Sat Nov 08, 10:03AM CST
Investing in biotech companies can be tricky, especially for investors who don't have a scientific background or who don't completely understand the process of bringing new drugs to the marketplace. Fortunately, the Fool is here to help. We asked...
AVNR: 13.19 (+0.17), SGEN: 35.62 (-0.43), GILD: 107.45 (+1.00), ABBV: 63.59 (+2.09), GSK: 45.17 (+0.26)
Jim Cramer's 'Mad Money' Recap: Here's Next Week's Game Plan
at The Street - Fri Nov 07, 7:19PM CST
Next week Cramer will be watching earnings from WhiteWave Foods, DR Horton and Wal-Mart, among many others.
DHI: 23.53 (+0.40), KMI: 38.70 (-0.05), HK: 3.25 (+0.01), KSS: 56.90 (-0.32), GE: 26.48 (+0.07), LMT: 186.77 (+0.62), AVAV: 29.06 (-0.75), WMT: 79.97 (+1.20), SNE: 20.56 (+0.94), M: 59.54 (-0.34), SDRL: 21.97 (+0.20), T: 35.07 (+0.16), W: 26.47 (+0.46), OPK: 8.57 (+0.25), QCOM: 69.63 (+0.37), TWTR: 40.04 (-0.27), EPR: 57.38 (+0.77), AAPL: 109.03 (+0.02), HSIC: 129.39 (+0.55), CSCO: 25.14 (-0.19), WFM: 47.63 (+0.82), CY: 10.13 (+0.05), MU: 32.95 (-0.06), SWKS: 60.90 (+1.02), IRM: 37.48 (-0.57), BAC: 17.32 (-0.04), MO: 49.97 (+0.10), CSX: 36.24 (+0.79), WWAV: 35.75 (-1.18), GILD: 107.45 (+1.00), TXN: 51.40 (+0.50), BPL: 79.62 (+0.32), JCP: 7.38 (-0.44), JWN: 72.49 (-0.94), BABA: 117.12 (+2.56)
Gilead (GILD) Submits HIV Combination Drug for FDA Review - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 5:50PM CST
Gilead Sciences, Inc. announced that it has submitted a New Drug Application to the FDA for its tenofovir alafenamide-based single tablet regimen.
AGN: 195.37 (-0.63), JNJ: 108.58 (+0.38), GILD: 107.45 (+1.00), ABBV: 63.59 (+2.09)
Final Glance: Biotechnology companies
AP - Fri Nov 07, 5:08PM CST
NEW YORK (AP) — Shares of some top biotechnology companies were down at the close of trading:
GILD: 107.46 (+1.01), AMGN: 161.99 (+1.74), CELG: 107.64 (+1.19)
Stock Movers: Why These 4 Medical Stocks Dived Today
at Investor's Business Daily - Fri Nov 07, 3:36PM CST
Raised eyebrows can lead to declining stock prices. Stocks On The Move down today include Salix Pharmaceuticals (SLXP), embroiled in drama as questions of accuracy and honesty cloud the drugmaker's weak Q3 results. Are its inventories accurate, and...
AGN: 195.37 (-0.63), VRX: 127.60 (+1.49), DVA: 74.53 (+0.04), GILD: 107.46 (+1.01), SLXP: 94.08 (+2.61), ICPT: 177.40 (+4.81), HUM: 132.47 (+1.89)
Pharmacyclics, Inc.'s Imbruvica Holds Its Own Against Gilead Sciences, Inc.'s Zydelig
Todd Campbell, The Motley Fool - Motley Fool - Fri Nov 07, 12:42PM CST
Source: Pharmacyclics Peak sales forecasts for Pharmacyclics' Imbruvica are estimated north of $3 billion, but investors had reason for pause last quarter when competitor Gilead Sciences launched Zydelig for the same indication. ...
JNJ: 108.57 (+0.37), PCYC: 132.97 (-0.52), GILD: 107.46 (+1.01), AZN: 73.24 (+0.36), GSK: 45.17 (+0.26), BMY: 58.54 (+0.22), CELG: 107.64 (+1.19)
Midday Glance: Biotechnology companies
AP - Fri Nov 07, 12:18PM CST
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.:
GILD: 107.46 (+1.01), AMGN: 161.99 (+1.74), CELG: 107.64 (+1.19)
Medifocus to Be Broadcast on BNN and Fox Business News on November 8th and 9th, 2014
Marketwire Canada - Fri Nov 07, 9:56AM CST
Medifocus, Inc. (OTCQX: MDFZF) (TSX VENTURE: MFS) is pleased to announce that it will be broadcast on both the BNN and the Fox Business News Network by Taylor Thoen, Executive Producer of BTV-Business TV. This broadcast will be a segment of the episode that will feature Gilead Sciences, Cynapsus Therapeutics, and biOasis Technologies Inc.
GILD: 107.46 (+1.01), MFS.VN: 0.090 (+0.005)
Humana Misses On ObamaCare Spending, Hep C Costs
at Investor's Business Daily - Fri Nov 07, 9:32AM CST
Humana (HUM) narrowed its earnings outlook for the year as its third-quarter revenue and earnings views fell short of analyst expectations on insurance and hepatitis C-related costs. Full-year earnings guidance is now in the range of $7.40-$7.60 per...
GILD: 107.45 (+1.00), AET: 83.21 (+0.92), HUM: 132.47 (+1.89)
Recent News posted below.
GILD Gilead Sciences Recent Headline News
Merck Down On Hepatitis C Data; Gilead Rises
at Investor's Business Daily - 1 hr 54 mins ago
Big pharma Merck (MRK) was down nearly 2% on the stock market today after the latest data from its hepatitis C pipeline underwhelmed the Street. On Sunday at the annual conference of the American Association for the Study of Liver Disease, Merck...
JNJ: 108.58 (+0.38), GILD: 107.47 (+1.02), ACHN: 12.54 (+2.43), MRK: 59.06 (-0.28), ABBV: 63.59 (+2.09), BMY: 58.54 (+0.22)
Watch for Shares of Gilead Sciences (GILD) to Approach Resistance at $109.86
Comtex SmarTrend(R) - 2 hrs 13 mins ago
Shares of Gilead Sciences (NASDAQ:GILD) opened today above their pivot of $107.24 and have already reached the first level of resistance at $108.16. Analysts will be watching for a cross of the next upside pivot targets of $109.86 and $112.48.
GILD: 107.47 (+1.02)
Buyside Buzz on Gilead, Regulus From This Year's Liver Meeting
at The Street - 2 hrs 28 mins ago
Here's a quick sketch of the Wall Street gossip mill emerging from the 'Liver Meeting.'
GILD: 107.47 (+1.02), ACHN: 12.55 (+2.44), RGLS: 23.00 (+0.92), ABBV: 63.59 (+2.09)
Early Glance: Biotechnology companies
AP - 2 hrs 40 mins ago
NEW YORK (AP) — Shares of some top biotechnology companies are up at 10 a.m.:
GILD: 107.47 (+1.02), AMGN: 162.00 (+1.75), CELG: 107.63 (+1.18)
Premarket: Stock Futures Mixed; Gilead Climbs On Merck News
at Investor's Business Daily - Mon Nov 10, 7:59AM CST
Stock futures shifted from thin, early losses to mixed trade ahead of Monday's open. Nasdaq 100 futures shed losses and were up a narrow 3.5 points. Dow futures remained 2.9 points below fair market value. S&P 500 futures were flat. The stock market...
WWAV: 35.75 (-1.18), GOGO: 15.46 (-1.18), GILD: 107.47 (+1.02), MRK: 59.06 (-0.28), CMCM: 20.90 (+0.70), DF: 16.36 (+1.94)
Earnings Forecast Buzz for Alibaba, Genworth Financial, Gilead Sciences, Zynga, Abercrombie & Fitch, and Plug Power
PR Newswire - Mon Nov 10, 7:45AM CST
EarningForecast.com has issued earnings forecast research with special focus on financial performance of the following stocks: Alibaba (NYSE:BABA), Genworth Financial (NYSE:GNW), Gilead Sciences (NASDAQ:GILD), Zynga (NASDAQ:ZNGA), Abercrombie & Fitch (NYSE:ANF), and Plug Power (NASDAQ
LUG). GILD: 107.47 (+1.02), PLUG: 5.24 (-0.06), ANF: 28.53 (-0.97), ZNGA: 2.45 (+0.02), GNW: 8.31 (-0.10), BABA: 117.12 (+2.56)
3 Drugs That Make Gilead Sciences' Harvoni Look Cheap
Todd Campbell, The Motley Fool - Motley Fool - Mon Nov 10, 6:31AM CST
Source: Bill Brooks/Flickr Healthcare costs are the leading cause of bankruptcy, so it's little wonder that people are up in arms over the cost of newly launched medicine like Gilead Sciences Harvoni. Gilead set the price of a 12-week...
GILD: 107.47 (+1.02), BMY: 58.54 (+0.22), NVS: 92.34 (+0.58)
Merck's Shortened Hep C Regimens Fall Short of Cure-Rate Goal
at The Street - Sun Nov 09, 5:23PM CST
A triple therapy combining two experimental Merck drugs with Gilead's Sovaldi yielded interim hepatitis C cure rates for ranging from 80% to 87% following six to eight weeks of treatment.
GILD: 107.47 (+1.02), MRK: 59.06 (-0.28), ABBV: 63.59 (+2.09)
5 Prescription Drugs Selling Like Hot Cakes
Todd Campbell, The Motley Fool - Motley Fool - Sun Nov 09, 9:01AM CST
Considering that 90% of prescription drugs being developed by biotechnology companies will fail during clinical trials, it can be tough to know which biotech stocks to seize upon and which stocks to shun. Instead of focusing on unproven...
MDVN: 109.33 (-3.44), JNJ: 108.58 (+0.38), BIIB: 325.03 (+4.28), PTLA: 27.33 (-0.06), GILD: 107.47 (+1.02), CELG: 107.64 (+1.19)
3 Biotech Stocks to Watch in November
Motley Fool Staff - Motley Fool - Sat Nov 08, 10:03AM CST
Investing in biotech companies can be tricky, especially for investors who don't have a scientific background or who don't completely understand the process of bringing new drugs to the marketplace. Fortunately, the Fool is here to help. We asked...
AVNR: 13.19 (+0.17), SGEN: 35.62 (-0.43), GILD: 107.45 (+1.00), ABBV: 63.59 (+2.09), GSK: 45.17 (+0.26)
Jim Cramer's 'Mad Money' Recap: Here's Next Week's Game Plan
at The Street - Fri Nov 07, 7:19PM CST
Next week Cramer will be watching earnings from WhiteWave Foods, DR Horton and Wal-Mart, among many others.
DHI: 23.53 (+0.40), KMI: 38.70 (-0.05), HK: 3.25 (+0.01), KSS: 56.90 (-0.32), GE: 26.48 (+0.07), LMT: 186.77 (+0.62), AVAV: 29.06 (-0.75), WMT: 79.97 (+1.20), SNE: 20.56 (+0.94), M: 59.54 (-0.34), SDRL: 21.97 (+0.20), T: 35.07 (+0.16), W: 26.47 (+0.46), OPK: 8.57 (+0.25), QCOM: 69.63 (+0.37), TWTR: 40.04 (-0.27), EPR: 57.38 (+0.77), AAPL: 109.03 (+0.02), HSIC: 129.39 (+0.55), CSCO: 25.14 (-0.19), WFM: 47.63 (+0.82), CY: 10.13 (+0.05), MU: 32.95 (-0.06), SWKS: 60.90 (+1.02), IRM: 37.48 (-0.57), BAC: 17.32 (-0.04), MO: 49.97 (+0.10), CSX: 36.24 (+0.79), WWAV: 35.75 (-1.18), GILD: 107.45 (+1.00), TXN: 51.40 (+0.50), BPL: 79.62 (+0.32), JCP: 7.38 (-0.44), JWN: 72.49 (-0.94), BABA: 117.12 (+2.56)
Gilead (GILD) Submits HIV Combination Drug for FDA Review - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 5:50PM CST
Gilead Sciences, Inc. announced that it has submitted a New Drug Application to the FDA for its tenofovir alafenamide-based single tablet regimen.
AGN: 195.37 (-0.63), JNJ: 108.58 (+0.38), GILD: 107.45 (+1.00), ABBV: 63.59 (+2.09)
Final Glance: Biotechnology companies
AP - Fri Nov 07, 5:08PM CST
NEW YORK (AP) — Shares of some top biotechnology companies were down at the close of trading:
GILD: 107.46 (+1.01), AMGN: 161.99 (+1.74), CELG: 107.64 (+1.19)
Stock Movers: Why These 4 Medical Stocks Dived Today
at Investor's Business Daily - Fri Nov 07, 3:36PM CST
Raised eyebrows can lead to declining stock prices. Stocks On The Move down today include Salix Pharmaceuticals (SLXP), embroiled in drama as questions of accuracy and honesty cloud the drugmaker's weak Q3 results. Are its inventories accurate, and...
AGN: 195.37 (-0.63), VRX: 127.60 (+1.49), DVA: 74.53 (+0.04), GILD: 107.46 (+1.01), SLXP: 94.08 (+2.61), ICPT: 177.40 (+4.81), HUM: 132.47 (+1.89)
Pharmacyclics, Inc.'s Imbruvica Holds Its Own Against Gilead Sciences, Inc.'s Zydelig
Todd Campbell, The Motley Fool - Motley Fool - Fri Nov 07, 12:42PM CST
Source: Pharmacyclics Peak sales forecasts for Pharmacyclics' Imbruvica are estimated north of $3 billion, but investors had reason for pause last quarter when competitor Gilead Sciences launched Zydelig for the same indication. ...
JNJ: 108.57 (+0.37), PCYC: 132.97 (-0.52), GILD: 107.46 (+1.01), AZN: 73.24 (+0.36), GSK: 45.17 (+0.26), BMY: 58.54 (+0.22), CELG: 107.64 (+1.19)
Midday Glance: Biotechnology companies
AP - Fri Nov 07, 12:18PM CST
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.:
GILD: 107.46 (+1.01), AMGN: 161.99 (+1.74), CELG: 107.64 (+1.19)
Medifocus to Be Broadcast on BNN and Fox Business News on November 8th and 9th, 2014
Marketwire Canada - Fri Nov 07, 9:56AM CST
Medifocus, Inc. (OTCQX: MDFZF) (TSX VENTURE: MFS) is pleased to announce that it will be broadcast on both the BNN and the Fox Business News Network by Taylor Thoen, Executive Producer of BTV-Business TV. This broadcast will be a segment of the episode that will feature Gilead Sciences, Cynapsus Therapeutics, and biOasis Technologies Inc.
GILD: 107.46 (+1.01), MFS.VN: 0.090 (+0.005)
Humana Misses On ObamaCare Spending, Hep C Costs
at Investor's Business Daily - Fri Nov 07, 9:32AM CST
Humana (HUM) narrowed its earnings outlook for the year as its third-quarter revenue and earnings views fell short of analyst expectations on insurance and hepatitis C-related costs. Full-year earnings guidance is now in the range of $7.40-$7.60 per...
GILD: 107.45 (+1.00), AET: 83.21 (+0.92), HUM: 132.47 (+1.89)
